RecruitingNCT06522334
Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria
Sponsor
Ludwig Boltzmann Institute for Lung Health
Enrollment
400 participants
Start Date
Feb 28, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. There are no additional interventions regarding this registry.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- diagnosis of interstitial lung disease
- written informed consent
Exclusion Criteria1
- to not comprehend and rightfully judge participation
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06522334
Related Trials
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT0717938096 locations
dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound
NCT062356451 location
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT032977751 location
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
NCT034788261 location
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT0638842162 locations